Clarinex

Clarinex is used to treat the symptoms of allergies, such as sneezing, watery eyes, and runny nose.

Product dosage: 5mg
Package (num)	Per pill	Price	Buy
60	$0.85	$51.00 (0%)	🛒 Add to cart
90	$0.72	$76.50 $65.00 (15%)	🛒 Add to cart
120	$0.67	$102.00 $80.00 (22%)	🛒 Add to cart
180	$0.61	$153.00 $109.00 (29%)	🛒 Add to cart
270	$0.57	$229.50 $153.00 (33%)	🛒 Add to cart
360	$0.54 Best per pill	$306.00 $196.00 (36%)	🛒 Add to cart
Synonyms Clarinex-d Clarinex reditabs

Clarinex (desloratadine) is a modern, second-generation antihistamine specifically formulated for the effective management of chronic allergic conditions. As the primary active metabolite of loratadine, it offers a refined therapeutic profile designed to provide long-lasting relief from a broad spectrum of allergic symptoms with a minimized side effect burden. Its non-sedating properties and once-daily dosing regimen support improved patient compliance and quality of life, making it a cornerstone in allergy management protocols prescribed by healthcare professionals worldwide.

Features

• Active Ingredient: Desloratadine 5 mg
• Pharmacological Class: Second-generation, peripherally selective H1-receptor antagonist
• Formulations: Film-coated tablets, orally disintegrating tablets (ODT), and syrup
• Dosing Regimen: Once-daily administration
• Onset of Action: Symptom relief typically begins within one hour post-dose
• Duration of Effect: Provides 24-hour coverage per dose
• Prescription Status: Available by prescription in most markets

Benefits

• Provides comprehensive, 24-hour relief from nasal and non-nasal symptoms of seasonal allergic rhinitis and chronic idiopathic urticaria
• Demonstrated efficacy in reducing sneezing, rhinorrhea, nasal pruritus, ocular itching, and tearing
• Non-sedating formulation allows for unimpaired daytime functioning and cognitive performance
• Minimal cardiotoxicity risk compared to first-generation antihistamines
• Suitable for long-term management of chronic allergic conditions
• Pediatric formulations available for children as young as 6 months

Common use

Clarinex is indicated for the relief of symptoms associated with seasonal allergic rhinitis (hay fever), perennial allergic rhinitis, and chronic idiopathic urticaria (hives of unknown origin). In allergic rhinitis, it effectively addresses nasal congestion, sneezing, rhinorrhea, and pruritus of the nose, palate, and eyes. For chronic urticaria, it reduces the severity and frequency of wheals (hives) and pruritus. Its use extends to managing allergic conjunctivitis symptoms and as adjunctive therapy in dermatological conditions with significant histaminergic components.

Dosage and direction

The recommended dosage for adults and adolescents (12 years and older) is 5 mg (one tablet or two teaspoonfuls of syrup) once daily. For children aged 6 to 11 years, the recommended dose is 2.5 mg (half tablet or one teaspoonful of syrup) once daily. Children aged 12 months to 5 years should receive 1.25 mg (half teaspoonful of syrup) once daily, while infants 6 to 11 months should receive 1 mg once daily. Administration may occur with or without food. For the orally disintegrating tablet formulation, place on tongue immediately after opening blister; administration with water is not required.

Precautions

Patients with hepatic or renal impairment should use Clarinex with caution; dosage adjustment may be necessary in severe cases. While Clarinex demonstrates minimal sedative effects, patients should exercise caution when engaging in activities requiring mental alertness until their response to the medication is established. Use during pregnancy should only be considered if the potential benefit justifies the potential risk to the fetus. Nursing mothers should consult their healthcare provider, as desloratadine is excreted in breast milk. Patients with phenylketonuria should note that the orally disintegrating tablets contain phenylalanine.

Contraindications

Clarinex is contraindicated in patients with known hypersensitivity to desloratadine, loratadine, or any component of the formulation. The orally disintegrating tablet formulation is contraindicated in patients with phenylketonuria due to its phenylalanine content. Concurrent administration with potent CYP3A4 inhibitors such as ketoconazole, erythromycin, or fluoxetine requires careful consideration and possible dosage adjustment due to potential increases in desloratadine exposure.

Possible side effect

The most commonly reported adverse reactions (≥2%) in clinical trials included pharyngitis, dry mouth, fatigue, somnolence, dysmenorrhea, and myalgia. Less frequent side effects may include tachycardia, palpitations, hypersensitivity reactions (rash, pruritus, urticaria), dizziness, insomnia, nervousness, and gastrointestinal disturbances. The incidence of sedation with Clarinex (6%) did not differ significantly from placebo (6%) in controlled clinical trials. Serious adverse events are rare but may include anaphylaxis and hepatic enzyme elevations.

Drug interaction

Although desloratadine has a low potential for interaction, concomitant use with erythromycin and ketoconazole resulted in increased plasma concentrations of desloratadine without clinically relevant effects. No meaningful interactions have been observed with azithromycin, fluoxetine, or cimetidine. Concurrent administration with alcohol did not potentiate impairment in psychomotor performance. However, caution is advised when combining with other central nervous system depressants. Desloratadine does not inhibit CYP2D6 or CYP3A4 isozymes at recommended doses.

Missed dose

If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent daily dosing at approximately the same time each day maintains optimal therapeutic plasma concentrations and symptom control.

Overdose

In the event of overdose, symptoms may include drowsiness, tachycardia, and headache. There is no specific antidote for desloratadine overdose. Management should include supportive and symptomatic treatment. Gastric lavage may be considered if performed soon after ingestion. Hemodialysis is unlikely to be beneficial due to desloratadine’s high protein binding and extensive tissue distribution. Patients should be monitored for cardiac parameters and provided with appropriate supportive care.

Storage

Store at controlled room temperature 20°-25°C (68°-77°F), with excursions permitted between 15°-30°C (59°-86°F). Keep the medication in its original container, tightly closed, and protected from moisture and light. Keep out of reach of children. Do not use after the expiration date printed on the packaging. For the orally disintegrating tablets, keep the blister package sealed until time of use to maintain stability.

Disclaimer

This information is provided for educational purposes only and does not constitute medical advice. Individual responses to medication may vary. Patients should consult with a qualified healthcare professional before starting, stopping, or changing any treatment regimen. The complete prescribing information should be reviewed before administration. Only a healthcare provider can determine the appropriate therapy based on individual patient characteristics and medical history.

Reviews

Clinical studies demonstrate that Clarinex provides effective relief of allergic symptoms with a favorable side effect profile. In randomized, double-blind, placebo-controlled trials involving over 2,300 patients, Clarinex 5 mg once daily significantly improved total symptom scores compared to placebo (p<0.01) for both seasonal allergic rhinitis and chronic idiopathic urticaria. Patient-reported outcomes indicate improved quality of life measures, particularly regarding sleep and daily activities. The non-sedating property is consistently reported as a significant advantage over first-generation antihistamines. Long-term studies (up to 6 months) confirm maintained efficacy without development of tolerance.